CD8A and neoplasm: Compared with a free dose of BLZ945, a single systemic dose of D-BLZ can reduce the tumor-promoting expression of TAMs and promote CD8+ cytotoxic T cell infiltration, resulting in prolonged survival in mice with a reduced dose of BLZ945 required to achieve the same effect.